Chromatin peptide for controlling expression of anoxic reaction gene through combining hypoxic response element

A technology of response element and hypoxia response, which is applied in the field of self-treatment of malignant tumors, and can solve the problems of hypoxia and insufficient energy supply.

Inactive Publication Date: 2017-02-01
北京京爱康科技有限公司
View PDF5 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Normal human cells maintain life and cell division can obtain sufficient energy through the surrounding blood vessels, but due to the rapid division of malignant tumor cells, hypoxia and insufficient energy supply are common in the tumor microenvironment

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Chromatin peptide for controlling expression of anoxic reaction gene through combining hypoxic response element
  • Chromatin peptide for controlling expression of anoxic reaction gene through combining hypoxic response element

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0043] The chromatin peptides of sequence numbers 1-5 in Table 2 were synthesized by the liquid-phase peptide synthesis method. The basic synthesis method is that a single N-α-protected amino acid is added repeatedly to the growing polypeptide chain, and the entire synthesis step is realized step by step. The synthesis process mainly includes protecting the amino acid N-α with a protecting group, then adding it to the polypeptide chain step by step, and anchoring the polypeptide chain on a chemically stable carrier. After the synthesis process is completed, the synthesized chromatin peptide can be separated from the solvent by centrifugal washing, then the protective group is removed, and finally the polypeptide chain is cleaved from the carrier for purification.

example 2

[0045] The animal drug efficacy test of the chromatin peptide that closes the hypoxia response element of the cell is tested to test the inhibitory effect of the chromatin peptide on the lung cancer of mice.

[0046] Lung cancer in mice transferred to the bone marrow, and radiotherapy could not be performed because the infection site was too extensive. Only the chromatin peptide corresponding to the NPA1 transcription factor was used for the test, and the molecular structure of the chromatin peptide was RKEKSRNAARSRR. From the next day, 0.2 mg was administered by intramuscular injection every day, and one month was taken as a course of treatment. During the course of treatment, antibiotics were used to control concurrent infection, and the tumor basically disappeared after three courses of continuous medication.

example 3

[0048] To determine the therapeutic effect of chromatin peptide RRKEKSRDAARSRR on rabbit liver malignant tumors. Malignant liver tumors in rabbits are not sensitive to radiotherapy. Administer 0.3 mg per day by intravenous injection. After 70 days of continuous administration, the tumor size becomes significantly smaller, and the tumor basically disappears after 30 days of continuous administration.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a chromatin peptide. The chromatin peptide substantially is peptide oligomers formed by degradation of a transcription factor of a hypoxic response element in a human body cell anoxic reaction and biological bionic molecules of the peptide oligomers. The transcription factor of the hypoxic response element in malignant tumor cells starts anaerobic respiration in cells, cell proliferation, blood vessel formation and inflammations, and provides energy and space for further expansion of cancer cells. The chromatin peptide generated by the degradation of the transcription factors and the bionic molecules of the chromatin peptide can specifically stop the cell hypoxic response in order to inhibit energy obtaining approaches of the malignant tumor cells, so the malignant tumor cells can naturally grow old toward death in order to realize the treatment purpose.

Description

technical field [0001] The invention relates to the field of human body self-treatment of malignant tumors, in particular to an active chromatin peptide capable of specifically blocking the expression of hypoxia response elements in gene expression cascades in the process of tissue renewal and cell proliferation. Background technique [0002] According to statistics, one person is diagnosed with cancer every 6 minutes across the country, about 8,550 people become new cancer patients every day, and one person dies of cancer every seven to eight people. In the next 10 years, the incidence and mortality of cancer in China will continue to rise steadily, and cancer will have a huge impact on people's health. Cancer treatment has become an important topic and an urgent task in the medical field all over the world. At present, there are various technologies for treating cancer. Surgery, radiotherapy and chemotherapy are the three main methods for treating cancer, but they lack spe...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07K14/47A61K38/17A61P35/00
CPCC07K14/47A61K38/00
Inventor 谭樵夫
Owner 北京京爱康科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap